EUVIMEDEUVIMED entdecken
Open Access

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma

Nathalie L Albert, Debie V Nelwan, Daniel F Fleischmann, Stefanie Quach, Katharina von Rohr, Lena Kaiser, Nico Teske, Lena M Unterrainer, Laura M Bartos, Viktoria C Ruf, Matthias Brendel, Markus J Riemenschneider und 11 weitere

Journal of Nuclear Medicine · 2023

DOI: 10.2967/jnumed.122.265247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Nathalie L Albert und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 18-kDa translocator protein (TSPO) is gaining recognition as a relevant target in glioblastoma imaging. However, data on the potential prognostic value of TSPO PET imaging in glioblastoma are lacking. Therefore, we investigated the association of TSPO PET imaging results with survival outcome in a homogeneous cohort of glioblastoma patients.

Methods

Patients were included who had newly diagnosed, histologically confirmed isocitrate dehydrogenase (IDH)-wild-type glioblastoma with available TSPO PET before either normofractionated radiotherapy combined with temozolomide or hypofractionated radiotherapy. SUVmax on TSPO PET, TSPO binding affinity status, tumor volumes on MRI, and further clinical data, such as O 6-alkylguanine DNA methyltransferase (MGMT) and telomerase reverse transcriptase (TERT) gene promoter mutation status, were correlated with patient survival.

Results

Forty-five patients (median age, 63.3 y) were included. Median SUVmax was 2.2 (range, 1.0-4.7). A TSPO PET signal was associated with survival: High uptake intensity (SUVmax > 2.2) was related to significantly shorter overall survival (OS; 8.3 vs. 17.8 mo, P = 0.037). Besides SUVmax, prognostic factors for OS were age (P = 0.046), MGMT promoter methylation status (P = 0.032), and T2-weighted MRI volume (P = 0.031). In the multivariate survival analysis, SUVmax in TSPO PET remained an independent prognostic factor for OS (P = 0.023), with a hazard ratio of 2.212 (95% CI, 1.115-4.386) for death in cases with a high TSPO PET signal (SUVmax > 2.2).

Conclusion

A high TSPO PET signal before radiotherapy is associated with significantly shorter survival in patients with newly diagnosed IDH-wild-type glioblastoma. TSPO PET seems to add prognostic insights beyond established clinical parameters and might serve as an informative tool as clinicians make survival predictions for patients with glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansMiddle AgedPrognosisIsocitrate DehydrogenaseTemozolomidePositron-Emission TomographyReceptors, GABA

Stichwörter der Autor:innen

gliomaprognosticationsurvival

Substanzen

Isocitrate DehydrogenaseTemozolomideTSPO protein, humanReceptors, GABA

Autor:innen und Institutionen

  • Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • German Cancer Consortium, Partner Site Munich, German Cancer Research Center, Munich, Germany.
  • Bavarian Cancer Research Center, Erlangen, Germany.
  • Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, Germany.
  • Institute of Neuropathology, Faculty of Medicine, LMU Munich, Munich, Germany.

Zitieren

APA

Albert, N. L., Nelwan, D. V., Fleischmann, D. F., Quach, S., von Rohr, K., Kaiser, L., Teske, N., Unterrainer, L. M., Bartos, L. M., Ruf, V. C., Brendel, M., Riemenschneider, M. J., Wetzel, C., Herms, J., Rupprecht, R., Thon, N., Tonn, J. C., Belka, C., Bartenstein, P., …, & Holzgreve, A. (2023). Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.122.265247

Vancouver

Albert NL, Nelwan DV, Fleischmann DF, Quach S, von Rohr K, Kaiser L, et al. Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.122.265247

BibTeX
@article{Albert2023,
  author = {Albert, Nathalie L and Nelwan, Debie V and Fleischmann, Daniel F and Quach, Stefanie and von Rohr, Katharina and Kaiser, Lena and Teske, Nico and Unterrainer, Lena M and Bartos, Laura M and Ruf, Viktoria C and Brendel, Matthias and Riemenschneider, Markus J and Wetzel, Christian and Herms, Jochen and Rupprecht, Rainer and Thon, Niklas and Tonn, Joerg-Christian and Belka, Claus and Bartenstein, Peter and von Baumgarten, Louisa and Niyazi, Maximilian and Unterrainer, Marcus and Holzgreve, Adrien},
  title = {Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  doi = {10.2967/jnumed.122.265247}
}
Kostenlos starten →